Lightchain Capital

Lightchain Capital is a venture capital firm based in Saint Louis, Missouri, founded in 2018. The firm specializes in investing in early-stage life sciences companies, particularly those focused on improving patient outcomes in cancer treatment. In addition to its primary focus on life sciences, Lightchain Capital also explores opportunities within the software sector, aiming to support innovative solutions that can enhance healthcare delivery and outcomes.

Drew Dennison

Managing Director

5 past transactions

Geneoscopy

Series C in 2025
Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

SimpleRose

Venture Round in 2023
SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.

AI Proteins

Seed Round in 2022
AI Proteins is a biotechnology company founded in 2021 and based in Boston, Massachusetts. The firm specializes in the design and engineering of synthetic mini protein therapeutics through an innovative drug discovery platform. Utilizing artificial intelligence, AI Proteins restructures protein therapeutics by creating synthetic proteins from the ground up, tailored to enhance their activity for various therapeutic applications. This approach allows for the rapid development of lead product candidates, providing clients with proteins that are cost-effective, durable, specific, and optimized for oral delivery.

NextRNA Therapeutics

Series A in 2022
NextRNA Therapeutics creates targeted therapeutics with the aim of discovering novel ncRNAs that cause disease. The company was founded in 2020 and is headquartered in Cambridge, Massachusetts.

SimpleRose

Venture Round in 2018
SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.